Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00065728 · ClinicalTrials.gov registry record · Phase 3
Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD
A Phase 3 study, sponsored by Alcon Research.
- Terminated
- Registry status
- Phase 3
- Development phase
- 111
- Enrollment target
NCT00065728: Clinical Trial Phase 3 study, sponsored by Alcon Research.
NCT00065728 is a Phase 3 study that was terminated before completion, run by Alcon Research. The registered enrollment target is 111 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00065728, a Phase 3 study, was terminated before completion, sponsored by Alcon Research.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 111 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the long-term efficacy and safety of posterior juxtascleral injections of open label Anecortave Acetate 15mg administered every 6 months.
Primary Outcome
Stable vision is defined as \< 15-letter loss of best-corrected visual acuity scores)
Interventions
- DRUG Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2003-06 |
| Est. Completion | 2008-10 |
| Phase | Phase 3 |
Why NCT00065728 stopped before completion
NCT00065728 is an interventional study that assigns participants to a tested intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 1 intervention - of which Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL is the first listed.
NCT00065728 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00065728 about?
NCT00065728 is a clinical study titled "Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD". The purpose of this study is to investigate the long-term efficacy and safety of posterior juxtascleral injections of open label Anecortave Acetate 15mg administered every 6 months.
What is the current status of trial NCT00065728?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 111 participants. The study started on 2003-06. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00065728?
The interventions under investigation include: Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL (DRUG).
Who is sponsoring clinical trial NCT00065728?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00065728's enrollment target sits among peer trials
111 1655th of 2000 higher than 344 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05263050 · 111 participants · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia